Reversible inhibitors of monoamine oxidase-A (RIMAs): Robust, reversible inhibition of human brain MAO-A by CX157

Medical Department, Brookhaven National Laboratory, Upton, NY, USA.
Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology (Impact Factor: 7.05). 11/2009; 35(3):623-31. DOI: 10.1038/npp.2009.167
Source: PubMed


Reversible inhibitors of monoamine oxidase-A (RIMA) inhibit the breakdown of three major neurotransmitters, serotonin, norepinephrine and dopamine, offering a multi-neurotransmitter strategy for the treatment of depression. CX157 (3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin-10,10-dioxide) is a RIMA, which is currently in development for the treatment of major depressive disorder. We examined the degree and reversibility of the inhibition of brain monoamine oxidase-A (MAO-A) and plasma CX157 levels at different times after oral dosing to establish a dosing paradigm for future clinical efficacy studies, and to determine whether plasma CX157 levels reflect the degree of brain MAO-A inhibition. Brain MAO-A levels were measured with positron emission tomography (PET) imaging and [(11)C]clorgyline in 15 normal men after oral dosing of CX157 (20-80 mg). PET imaging was conducted after single and repeated doses of CX157 over a 24-h time course. We found that 60 and 80 mg doses of CX157 produced a robust dose-related inhibition (47-72%) of [(11)C]clorgyline binding to brain MAO-A at 2 h after administration and that brain MAO-A recovered completely by 24 h post drug. Plasma CX157 concentration was highly correlated with the inhibition of brain MAO-A (EC(50): 19.3 ng/ml). Thus, CX157 is the first agent in the RIMA class with documented reversible inhibition of human brain MAO-A, supporting its classification as a RIMA, and the first RIMA with observed plasma levels that can serve as a biomarker for the degree of brain MAO-A inhibition. These data were used to establish the dosing regimen for a current clinical efficacy trial with CX157.

Download full-text


Available from: Youwen Xu

  • No preview · Article ·
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Major depressive disorder (MDD) is estimated by the World Health Organization to be the fourth leading cause of loss of disability-adjusted life years. In the National Comorbidity Survey, MDD is the most common mental illness and is one of the most common and disabling of all illnesses (Kessler et al., 1994). The lifetime risk for MDD is 10–25% in women and 5–12% in men, and at any point its prevalence is 5–9% in women and 2–3% in men. Given the widespread and disabling nature of the illness, MDD is of great public health concern. The first useful antidepressants, imipramine and isoniazid, were serendipitously found to have antidepressant properties in the 1950s. These discoveries – coupled with the observation that reserpine, which depletes monoamines, induced depres-sion – led to the development of the monoamine hypothesis of depression. This led to the rational development of drugs which affect central nervous system monoamines, primarily norepinephrine (noradrenaline), serotonin (5-HT), and dopamine. The tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) formed the foundation for several decades of pharmacologic treat-ments for depression, although their side-effects (including lethality in overdose in the case of TCAs, and strict dietary restriction to avoid hypertensive crises in the case of MAOIs) limited their utility and tolerability. Pharmaceutical research focused on the development of drugs with improved tolerability and safety. Next-generation drugs such as trazodone, a 5-HT 2 -receptor antagonist, were an incre-mental improvement, but not until the arrival to the market in 1988 of the first selective serotonin reuptake inhibitor (SSRI), fluoxetine (Prozac), did the use of antidepressants markedly change. Several other SSRIs followed, including parox-etine (Paxil), sertraline (Zoloft), fluvoxamine (Luvox), citalopram (Celexa), and escitalopram (Lexapro).
    Full-text · Article ·
  • [Show abstract] [Hide abstract]
    ABSTRACT: Monoamine oxidase (MAO) is an integral protein of outer mitochondrial membranes and occurs in neuronal and nonneuronal cells in the brain and in peripheral organs. It oxidizes amines from both endogenous and exogenous sources, thereby influencing the concentration of neurotransmitter amines as well as many xenobiotics. It occurs in two subtypes, MAO A and MAO B, which are different gene products and have different substrate and inhibitor specificities. Both MAO A and B can be imaged and quantified in the living human brain using positron emission tomography (PET) and radiotracers labeled with carbon-11. PET studies have been carried out to measure the effects of age, MAO inhibitor drugs, tobacco smoke exposure, and other factors on MAO activity in the human brain.
    No preview · Article · Aug 2002 · Methods
Show more

We use cookies to give you the best possible experience on ResearchGate. Read our cookies policy to learn more.